John Butler, Akebia CEO
April 7, 2022 10:00 AM EDTUpdated 11:07 AM
R&D
FDA+

In a one-two gut punch af­ter kid­ney drug CRL, Ake­bia slapped with par­tial hold and will lay off 42% of staff

Max Gelman

Senior Editor

Snakebit af­ter a sur­pris­ing CRL for its lead pipeline pro­gram last week, Ake­bia Ther­a­peu­tics is fac­ing an­oth­er road­block at the FDA — and lay­offs are now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times